RedHill Biopharma Ltd RDHL shares are down after the company announced a registered direct offering of 1.3 million American Depositary Shares, each ADS representing four hundred (400) ordinary shares, at a purchase price of $1.35 per ADS (or ADS equivalent), in a registered direct offering.
The company has also entered into a definitive agreement with a certain holder of its existing Class A warrants exercisable for 1.5 million ADSs, in the aggregate, to exercise its warrants at a reduced exercise price of $1.35 per ADS.
The gross proceeds to the company from the transactions are expected to be approximately $3.8 million, which will be used for general working capital, acquisitions, R&D, and general corporate purposes.
The company also announced that opaganib has been awarded a further $1.7 million in U.S. Government funding via a Small Business Innovation Research (SBIR) grant to the company's development partner, Apogee Biotechnology.
This SBIR grant will support research to further the development of opaganib as a medical countermeasure for gastrointestinal acute radiation syndrome.
The SBIR grant is in addition and complementary to the multimillion-dollar-valued U.S. Government Radiation and Nuclear Countermeasures Program product pipeline development contract awarded to opaganib following its selection by the RNCP for ARS development.
Price Action: RDHL shares are down 22.1% at $1.44 on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.